A 58-year-old woman with CKD stage 5 (eGFR 12 mL/min/1.73m²) on hemodialysis presents with fatigue and dyspnea. Hemoglobin is 8.2 g/dL, MCV 82 fL, serum iron 45 mcg/dL (normal 60–170), ferritin 850 ng/mL (normal 30–300), TSAT 18% (normal >20%), reticulocyte count 0.8% (normal 0.5–2.5%). She has been on erythropoietin-stimulating agent (ESA) for 6 months without improvement. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: ESA Hyporesponsiveness with Functional Iron Deficiency **Key Point:** This patient meets criteria for **ESA hyporesponsiveness** (inadequate Hb response despite ESA therapy) combined with **functional iron deficiency** (low TSAT despite elevated ferritin). ### Iron Status Interpretation | Parameter | Value | Normal | Interpretation | |-----------|-------|--------|----------------| | Serum Iron | 45 mcg/dL | 60–170 | **Low** | | Ferritin | 850 ng/mL | 30–300 | **Elevated** (inflammation/stores) | | TSAT | 18% | >20% | **Low** (functional deficiency) | | Reticulocyte Count | 0.8% | 0.5–2.5% | Blunted response to anemia | **Clinical Pearl:** In CKD, ferritin is an **acute phase reactant** and may be falsely elevated due to inflammation or infection, masking true iron deficiency. TSAT <20% is the more reliable indicator of functional iron deficiency and is the strongest predictor of ESA response. ## Diagnostic Algorithm for ESA Hyporesponsiveness ```mermaid flowchart TD A[CKD anemia on ESA, Hb not improving]:::outcome --> B{Check TSAT}:::decision B -->|TSAT < 20%| C[Functional iron deficiency]:::outcome B -->|TSAT ≥ 20%| D[Assess for other causes]:::action C --> E[IV iron supplementation]:::action D --> F[Check: infection, inflammation, PTH, B12/folate, hemolysis]:::action F --> G[Treat underlying cause]:::action E --> H[Recheck Hb + iron indices in 4 weeks]:::action H --> I{Response?}:::decision I -->|Yes| J[Continue iron + ESA]:::outcome I -->|No| K[Consider ESA resistance workup]:::action ``` ## Why IV Iron is the Next Step **High-Yield:** ESA hyporesponsiveness in CKD is most commonly due to: 1. **Iron deficiency** (absolute or functional) — 40–50% of cases 2. Infection/inflammation — 20–30% 3. Inadequate dialysis — 10–15% 4. Occult blood loss — 10% 5. B12/folate deficiency — 5% **Mnemonic:** **FISH** — **F**erritin, **I**nfection, **S**econdary hyperparathyroidism, **H**emolysis/Hemoglobinopathy This patient's low TSAT (18%) indicates **functional iron deficiency** — iron is sequestered in reticuloendothelial cells and unavailable for erythropoiesis. IV iron (e.g., iron sucrose 200 mg weekly × 5 weeks) bypasses this compartmentalization and restores iron availability to bone marrow, improving ESA responsiveness. **Clinical Pearl:** Oral iron is ineffective in CKD due to poor GI absorption and GI side effects; IV iron is the standard in dialysis patients. ## Why Not the Other Options? | Option | Reason | |--------|--------| | **Increase ESA dose** | Blindly escalating ESA without addressing iron deficiency will not improve response and increases risk of thrombosis, hypertension, and cost. Iron deficiency must be corrected first. | | **Switch ESA agent** | Different ESA agents (darbepoetin, peginesatide) are not superior to epoetin in hyporesponsive patients; the underlying cause (iron deficiency) must be addressed. Switching without iron repletion will fail. | | **Transfuse and stop ESA** | RBC transfusion is a last resort for symptomatic severe anemia (Hb <7 g/dL) and risks iron overload, alloimmunization, and infections. This patient's Hb is 8.2 g/dL and is manageable with iron + ESA optimization. | ## Management Summary 1. **Initiate IV iron** (iron sucrose 200 mg weekly × 5 weeks or iron isomaltoside 750 mg × 2 doses) 2. **Investigate for occult infection** (CRP, procalcitonin, blood cultures if febrile) 3. **Assess dialysis adequacy** (Kt/V, URR) 4. **Check B12, folate, reticulocyte count** (rule out hemolysis) 5. **Recheck CBC + iron indices in 4 weeks** 6. **Titrate ESA dose** only after iron repletion and confirmation of response [cite:KDIGO 2021 Anemia in CKD Guidelines], [cite:Harrison 21e Ch 280]